porno izle
erotik film
women desperate to piss ava addams mom porn sa akin ang gabi

Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

AMR Action Fund | $1B USD generated

The AMR Action Fund totals approx. $1B USD and has been generated by 23 pharma companies in partnership with the WHO. This fund will focus on treatments for drug resistant infections, a major threat to global health and already responsible for 700,000 deaths per year.

Lloyd Payne PhD, Evotec' s EVP Head of Anti-Infectives Operations, discusses what this funding means for the future of AMR: | #researchneverstops #AMR #antimicrobialresistance 

New England Biolabs’ SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit Enables Visual Detection of Novel Coronavirus In 30 Minutes

The research use only kit can be used as a simple alternative to RT-qPCR for SARS-CoV-2 analysis.

Read the rest of entry »

University of Birmingham spinout announces collaboration and licence agreement to develop precision cancer treatments

University of Birmingham spinout Revitope Oncology Inc has announced a research collaboration and licence agreement with leading Chinese biopharmaceutical company Junshi Biosciences to develop precision cancer therapies that harness the body’s immune response to kill cancer cells while leaving healthy body tissues untouched. Revitope will leverage its proprietary protein engineering platform with Junshi’s novel antibody components to develop first-in-class dual antigen targeting cancer therapies.   Revitope will receive up to $160 million per molecule in milestones and royalties on net sales of 10%.  Junshi has also committed to acquire a 9.99% stake in Revitope for $10 million. Revitope’s technology, known as the T-cell engager antibody circuit (TEAC), has the potential to significantly improve outcomes for millions of cancer patients.  The technology splits antibodies into two halves which are programmed to recognise different antigens.  The two halves ...

Read the rest of entry »

Health Leadership in a Time of COVID: An interview with Asad Mohsin Ali, Director for UK and Ireland at Ipsen

In the last few months, almost every business has had to make some huge adjustments to how it operates. However, organisations in the healthcare sector have been thrust into the spotlight. They are not only having to ensure they maintain their critical services to patients and healthcare operators, but also are having to navigate a virus pandemic and look after their employees.

Read the rest of entry »

Domainex Licenses Small Molecule Inhibitor for Treatment of Acute Myeloid Leukemia to Invivoscribe's New Division for Drug Development

    San Diego, California and Saffron Walden, UK:  Invivoscribe, Inc., an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine. This new engine will combine with its in-house expertise in diagnostics development and worldwide access to patients and clinical testing capabilities to accelerate drug development.   Invivoscribe’s therapeutics division also announced today that the company has in-licensed technology involving a preclinical molecule and associated small molecules from Domainex Ltd. Domainex is a rapidly growing, well established integrated drug discovery service company in the UK that has utilized its novel, proprietary technologies to develop a first-in-class small molecule program against a difficult to target enzyme. Under the license agreement, Invivoscribe will develop and commercialize certain molecules generated by Domainex as oral immunotherapy agents to treat hem ...

Read the rest of entry »

Innovate UK launches the next round of the Biomedical Catalyst - launch on 27th July

£30 Million is available to support industry-led research and development projects that seek to provide solutions to Health and Care challenges.

Read the rest of entry »

Absolute Antibody and University of Zurich Collaborate to Offer Synthetic Nanobodies Against SARS-CoV-2 Receptor Binding Domain

Recombinant engineered antibodies for COVID-19 diagnostics and therapeutic development

Read the rest of entry »

RSSL Responsible Person Training Course Awarded Cogent Gold Standard

Reading Scientific Services Ltd (RSSL) has received the MHRA-recognised Cogent Gold Standard approval for its Responsible Person (RP) training course. The announcement follows a rigorous 18-month process, during which RSSL successfully developed and mapped all of its course material against the Gold Standard requirements.

Read the rest of entry »

ARAB Health 2021 Global Exhibition: 1 - 4 February 2021 - OBN Members Discount

Take advantage of this discount to attend the premier Middle East Conference of the year

Read the rest of entry »

Oxford Nanopore announce 'Virtual Nanopore Day, Edinburgh' which is taking place on Tuesday 14th July

This event will kick off with an introduction from Danielle Folkard, Oxford Nanopore Technologies Ltd. and a Q&A session. Attendees will then hear from local users about their research using nanopore sequencing

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.